Previous 10 | Next 10 |
BOTHELL, Wash., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will be presenting preclinical data demo...
Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...
Summary Athira Pharma’s stock has sold off some months ago on its Alzheimer’s drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable efficacy, which appears stronger than 27% slowing of cognit...
Summary Alzheimer's Disease is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. In this piece, we dive into 8 of the most impactful and promising trials. Introduction Alzheimer's disease is the largest unmet...
Athira Pharma ( NASDAQ: ATHA ) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an int...
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk Updated study well powered for primary endpoint with addition of fewer than 150 patients Company targets completion of enrollment in mid-2023 and...
Adapting study to focus on the evaluation of fosgonimeton monotherapy Conducting an independent, unblinded interim analysis to confirm sample size for primary endpoint of Global Statistical Test (GST) BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (...
The following slide deck was published by Athira Pharma, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Athira Pharma, Inc. 2022 Q2 - Results - Earnings Call Presentation
Athira Pharma press release ( NASDAQ: ATHA ): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021. For further details see: Athira Pharma GAAP EPS of -$0.65
Presented clinical and preclinical data at Alzheimer’s Association International Conference 2022 Strong balance sheet to support clinical development pipeline BOTHELL, Wash., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-s...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...